Arash Grakoui, PhD

Associate Professor of Medicine

Emory University School of Medicine


Hepatitis C virus (HCV) infection chronicity and its detrimental long-term sequelae now comprise the leading indication for liver transplantation in the United States. There are currently nearly 4 million HCV carriers in the U.S., an estimated 170 million people worldwide, and in the next few years, the number of annual U.S. deaths from HCV-induced liver cancer may surpass deaths caused by HIV. The paradoxical observation that HCV establishes a persistent infection despite the presence of humoral and cellular immune responses has provided the impetus to rigorously explore the host response to HCV. Our laboratory aims first to understand the role of the immune response in combating hepatitis C virus infection and second, to elucidate methods of augmenting the natural immune response to prevent HCV-associated liver disease and cancer.